Hepatitis%20a%20-and-%20e Management

Management

Prevention

PREVENTION AND POST-EXPOSURE PROPHYLAXIS OF HEPATITIS A and E
Patient Group for Whom Prevention or Post-exposure Prophylaxis is Recommended	Recommended Prevention or Post-exposure Prophylaxis Regimen
Prevention
Hepatitis A Susceptible persons traveling to hepatitis A virus (HAV)-endemic areas Lab researchers potentially exposed to HAV Unvaccinated and immunocompromised children (suboptimal response) Men who have sex with men (MSM) Illegal drug users (both injection and non-injection drug users) Homeless individuals Individuals with potential close contact with an international adoptee Persons with chronic liver disease, including persons with chronic HBV and HCV infection who have evidence of chronic liver disease Patients with HIV infection	Hepatitis A vaccine¹
Hepatitis E Individuals susceptible to HEV infection and HEV-related diseases	Hepatitis E recombinant vaccine (approved only in China)
Post-exposure Prophylaxis
Hepatitis A Unvaccinated or nonimmune persons exposed to HAV through household or sexual contact or by sharing illegal drugs with a person who has hepatitis A²	Administer hepatitis A vaccine as soon as possible, within 2 weeks after exposure A single IM dose of human immunoglobulin (Ig) may be given together with hepatitis A vaccine to individuals >40 years old, immunocompromised patients, or those with chronic liver disease

¹Postvaccination serologic testing is not indicated because most persons respond to the vaccine
²A person who has had 1 dose of hepatitis A vaccine at least 1 month before exposure to HAV does not need Ig

Product Highlight - Ravida

13 Sep 2022

Ravidasvir 200 mg tab

Long COVID: What we have learned so far

Prof. Ghassan Dbaibo, 27 Apr 2023

The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.

Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma

Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).